Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 9, 2017, Pages 1219-1221

  Calverley, Peter M A ^a   Tetzlaff, Kay ^b,c,d   Vogelmeier, Claus ^e   Fabbri, Leonardo M ^f   Magnussen, Helgo ^g   Wouters, Emiel F M ^h   Mezzanotte, William ^f   Disse, Bernd ^a   Finnigan, Helen ^b   Asijee, Guus ^b   Hallmann, Christoph ^a   Watz, Henrik ^c  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f Mitglied im DZL   (Germany)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; MEDICAL HISTORY; PRIORITY JOURNAL; TREATMENT RESPONSE; DEPRESCRIPTION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; DEPRESCRIPTIONS; DISEASE PROGRESSION; EOSINOPHILIA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85018950240     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201612-2525LE     Document Type: Letter

References (8)

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med 2017;195:557-582.
2. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:523-525.
3. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am J Respir Crit Care Med 2016;193:965-974.
4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363: 1128-1138.
5. Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4: 390-398.
6. Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Disse B, Finnigan H, Asijee GM, Watz H. Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD [abstract]. Eur Respir J 2016;48(Suppl 60): OA1973.
7. Magnussen H, Watz H, Kirsten A, Decramer M, Dahl R, Calverley PMA, Towse L, Finnigan H, Tetzlaff K, Disse B. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 2014;108:593-599.
8. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, et al.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371: 1285-1294.